Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
Morgan R Godin, Preeya K Gupta Department of Ophthalmology, Division of Cornea and Refractive Surgery, Duke University Eye Center, Durham, NC, USA Abstract: A new topical ophthalmic medication, lifitegrast 5%, was recently approved by the US Food and Drug Administration for use in dry eye patients...
Enregistré dans:
Auteurs principaux: | Godin MR, Gupta PK |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/eccfef0b80344d40b251c2575f854896 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
par: Nichols KK, et autres
Publié: (2018) -
Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
par: Semba CP, et autres
Publié: (2016) -
Evolución histórica del Opus Dei
par: Moncada, Alberto
Publié: (2007) -
Existencia cristiana y mundo jalones para una reflexiín teológica sobre el Opus Dei /
par: Illanes Maestre, José Luis
Publié: (2003) -
El Beato Álvaro del Portillo y la Universidad /
Publié: (2015)